According to Illumina's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.59752. At the end of 2022 the company had a P/E ratio of -7.22.
Year | P/E ratio | Change |
---|---|---|
2022 | -7.22 | -109.66% |
2021 | 74.7 | -9.5% |
2020 | 82.6 | 69.54% |
2019 | 48.7 | -8.72% |
2018 | 53.4 | 21.15% |
2017 | 44.1 | 8.72% |
2016 | 40.5 | -32.66% |
2015 | 60.2 | -16.22% |
2014 | 71.8 | -35.06% |
2013 | 111 | 142.71% |
2012 | 45.6 | 6.14% |
2011 | 42.9 | -31.55% |
2010 | 62.7 | 20.6% |
2009 | 52.0 | -31.13% |
2008 | 75.5 | -761.29% |
2007 | -11.4 | -125.78% |
2006 | 44.3 | -260.21% |
2005 | -27.6 | -50.42% |
2004 | -55.8 | 572.34% |
2003 | -8.29 | 222.41% |
2002 | -2.57 | -81.84% |
2001 | -14.2 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Thermo Fisher Scientific TMO | 37.4 | -913.30% | ๐บ๐ธ USA |
Agilent Technologies A | 36.0 | -882.01% | ๐บ๐ธ USA |
Quest Diagnostics
DGX | 19.9 | -532.55% | ๐บ๐ธ USA |
Danaher DHR | 30.7 | -768.39% | ๐บ๐ธ USA |
PerkinElmer
PKI | 15.0 | -425.54% | ๐บ๐ธ USA |
Translate Bio
TBIO.defunct | N/A | N/A | ๐บ๐ธ USA |
Pacific Biosciences
PACB | -1.16 | -74.74% | ๐บ๐ธ USA |
Luminex LMNX | N/A | N/A | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.